Building Value from Concept to Clinic.
Lobe Sciences advances high-potential drug candidates through a disciplined pharmaceutical development platform—progressing assets from early development to clinic through focused subsidiary companies.
CSE: LOBE | OTCQB: LOBEF | FWB: LOBE.F
ABOUT US
A Disciplined Pharmaceutical Development Platform
Lobe Sciences Ltd. is a Canadian public biopharmaceutical company structured to identify, develop, and de-risk differentiated therapeutic assets through focused subsidiary companies. Our capital-efficient model isolates programs, aligns incentives, and advances each asset through defined clinical and regulatory milestones before partnering with established commercial organizations.
CSE
LOBE
OTCQB
LOBEF
FWB
LOBE.F
OUR DEVELOPMENT PLATFORM
A Proven Development Approach
We operate a structured, capital-efficient development approach designed to advance promising assets to clear value-creation milestones, then partner with established organizations for commercialization. By concentrating on development rather than sales infrastructure, Lobe Sciences applies scientific rigor, regulatory clarity, and repeatable execution to create long-term value for patients, partners, and shareholders.
01
Identify & Acquire
We selectively identify differentiated assets that address clear unmet medical needs and demonstrate strong scientific rationale, regulatory clarity, and intellectual property potential.
02
Design & Develop
We design capital-efficient, milestone-driven development strategies that integrate preclinical work, CMC planning, clinical study design, and early regulatory engagement.
03
De-risk & Deliver
We advance programs toward value inflection points by generating proof-of-concept data, establishing safety and pharmacokinetics, securing regulatory designations where applicable, and building defensible intellectual property.
04
Planning & Executing
We execute programs with disciplined project management, data-driven decision-making, and adaptive development strategies that balance clinical, regulatory, and commercial considerations.
05
Strategic Partnerships
We partner with established organizations that possess the infrastructure, expertise, and long-term commitment required to bring therapies successfully to patients.
Investor Email Alerts
OUR COMPANIES
Focused Subsidiary Platforms
Each subsidiary is intentionally structured to isolate risk, attract aligned capital, and advance programs independently through defined development milestones.
64% OWNED
Advancing L-130 (Psilocin Mucate) for the treatment of chronic cluster headache—one of the most painful and underserved neurological conditions.
SUBSIDIARY
Developing S-100, a lipid-based therapeutic for sickle cell disease, along with Altemia®, a medical food for nutritional support in SCD management.
Interested in Learning More?
Connect with our team to learn about investment opportunities and company developments.